Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cencora, Inc. (COR)
:COR
COR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$214.77 - $262.26
Previous CloseN/A
Volume440.68K
Average Volume (3M)1.53M
Market Cap
$46.82B
Enterprise Value$48.81B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)34.4
Beta0.33
Next Earnings
Apr 30, 2025EPS Estimate
4.06Last Dividend Ex-Date
Feb 14, 2025Dividend Yield0.86%
Share Statistics
EPS (TTM)7.03
Shares Outstanding193,917,080
10 Day Avg. Volume1,939,175
30 Day Avg. Volume1,529,939
Standard Deviation0.06
R-Squared0.17
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.15
Price to Cash Flow (P/CF)-4.30
P/FCF Ratio0.00
Enterprise Value/Market Cap1.04
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit4.93
Enterprise Value/Ebitda15.38
Forecast
1Y Price Target
$281.10Price Target Upside14.54% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
---
Bulls Say, Bears Say
Bulls Say
Customer AcquisitionCOR recently acquired Meijer as a new customer, potentially boosting distribution revenue significantly.
Earnings PerformanceCencora continued its beat-and-raise streak with very strong FY1Q'25 results, increasing FY25 guidance for the second time in a month.
Revenue GuidanceCOR raised its FY25 segment revenue guidance from 7-9% to 9-11% growth, signaling strong confidence in future performance.
Bears Say
Global Specialty LogisticsThe global specialty logistics business, World Courier, experienced a decrease in EBIT, indicating challenges despite overall company strength.
International PerformanceInternational was the only area where guidance fell short, with weak clinical trial volumes anticipated through the first half of the fiscal year.
US Healthcare RevenueExpected deceleration of U.S. Healthcare revenue growth is tied to assumptions that GLP-1 drug sales growth may slow.
---
Ownership Overview
6.86% Insiders
27.31% Mutual Funds
27.64% Other Institutional Investors
14.23% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
COR FAQ
What was Cencora, Inc.’s price range in the past 12 months?
Cencora, Inc. lowest stock price was $214.77 and its highest was $262.25 in the past 12 months.
What is Cencora, Inc.’s market cap?
Cencora, Inc.’s market cap is $46.82B.
When is Cencora, Inc.’s upcoming earnings report date?
Cencora, Inc.’s upcoming earnings report date is Apr 30, 2025 which is in 69 days.
How were Cencora, Inc.’s earnings last quarter?
Cencora, Inc. released its earnings results on Feb 05, 2025. The company reported $3.73 earnings per share for the quarter, beating the consensus estimate of $3.502 by $0.228.
Is Cencora, Inc. overvalued?
According to Wall Street analysts Cencora, Inc.’s price is currently Undervalued.
Does Cencora, Inc. pay dividends?
Cencora, Inc. pays a Quarterly dividend of $2.118 which represents an annual dividend yield of 0.86%. See more information on Cencora, Inc. dividends here
What is Cencora, Inc.’s EPS estimate?
Cencora, Inc.’s EPS estimate is 4.06.
How many shares outstanding does Cencora, Inc. have?
Cencora, Inc. has 193,917,080 shares outstanding.
What happened to Cencora, Inc.’s price movement after its last earnings report?
Cencora, Inc. reported an EPS of $3.73 in its last earnings report, beating expectations of $3.502. Following the earnings report the stock price went up 0.681%.
Which hedge fund is a major shareholder of Cencora, Inc.?
Currently, no hedge funds are holding shares in COR
---
Cencora Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$281.10 (14.54% Upside)
$281.10 (14.54% Upside)
Blogger Sentiment
Bullish
COR Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 2.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $327.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.8%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
6.86%
12-Months-Change
Fundamentals
Return on Equity
245.32%
Trailing 12-Months
Asset Growth
6.75%
Trailing 12-Months
Company Description
Cencora, Inc.
Cencora, Inc. engages provision of pharmaceutical products and business solutions that improve access
to care. It operates through the Pharmaceutical Distribution Services and Other segments. The Pharmaceutical
Distribution Services segment distributes a comprehensive offering of brand-name, specialty brand-name & generic
pharmaceuticals, over-the-counter healthcare products, home healthcare supplies & equipment, outsourced compounded
sterile preparations, and related services to a wide variety of healthcare providers, including acute care hospitals and
health systems, independent & chain retail pharmacies, mail order pharmacies, medical clinics, long-term care & alternate
site pharmacies, and other customers. The Other segment focuses on global commercialization services and animal health and
includes ABCS, World Courier, and MWI. The company was founded in 1947 and is headquartered in Chesterbrook, PA.
---
COR Company Deck
---
COR Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue and EPS growth, particularly in the U.S. healthcare solutions segment, and the strategic acquisition of RCA. Despite these positive developments, there were challenges such as decreased gross profit margin, subdued international operation results, and negative free cash flow. The overall sentiment is cautiously optimistic with strong underlying performance offset by some challenges.Read More>---
COR Revenue Breakdown
89.54% U.S. Healthcare Solutions
10.46% International Healthcare Solutions
---
COR Stock 12 Month Forecast
Average Price Target
$281.10
▲(14.54% Upside)
Technical Analysis
Best Analysts Covering COR
1 Year
1 Year Success Rate
40/42 ratings generated profit
1 Year Average Return
+19.43%
reiterated a buy rating 3 days ago
Copying Eric Coldwell's trades and holding each position for 1 Year would result in 95.24% of your transactions generating a profit, with an average return of +19.43% per trade.
---